CSE’s Anil Mall chats with Chris Bunka, Chairman and CEO of Lexaria Bioscience Corp. (CSE:LXX) to discuss the company’s recently closed financing of US$11 million and the opportunities that capital has afforded the company’s ability to further prove out the effectiveness of its patented DehydraTECH™, drug delivery technology across multiple classes of bioactive substances or drugs.
Here’s an overview of what Anil and Chris cover in this edition of the #HashtagFinance podcast:
0:00 – Introducing Chris Bunka and Lexaria Bioscience
2:25 – Recent listing on NASDAQ and financing
4:40 – The team at Lexaria
7:30 – Chris’ background and what drives him
11:58 – DehydraTECH™ – drug enhancement delivery system
16:11 – Competing with Nanotechnology
18:50 – Utilizing patents with CBD
26:00 – Developing smoking alternatives w/ oral nicotine
33:00 – CBD from hemp
36:00 – Improved anti-viral drug delivery
40:15 – working with universities
44:20 – The best team he has ever worked with
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.
DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oralbased nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide.
For more information, please visit www.lexariabioscience.com.
CSE’s Phillip Shum chats with TAAT Lifestyle & Wellness Director Joe Deighan, who discusses their recent public listing and subsidiary Taat Herb Co. who manufacture and sell premium hemp products including hemp cigarettes made from a proprietary blend of premium hemp. Here’s an overview of what they cover in this podcast: 1:38 – Joe’s background…
CSE’s Anil Mall chats with Silas Garrison, CEO of HealthSpace Data Systems Ltd. (CSE:HS) to discuss his personal ambitions to revolutionize efficiencies across various levels of government utilizing HealthSpace’s unique SAAS solutions. Here’s an overview of what Anil and Silas cover in this edition of the #HashtagFinance podcast: 0:00 – Introducing Silas Garrison and HealthSpace…
(CSE:HS)
CSE’s Anil Mall chats with Jeff Stevens, CEO of Psyched Wellness Ltd. (CSE:PSYC) to discuss the company’s objective to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. Jeff also shares how they are developing a line of Amanita Muscaria-derived water-based extracts, teas…
Psyched Wellness Ltd (CSE:PSYC)
